Document is current
Any future updates will be listed below
-
Authors
Røst, Lisa M. https://orcid.org/0000-0003-3980-8667
Ræder, Synnøve B.
Olaisen, Camilla https://orcid.org/0000-0003-2266-4150
Søgaard, Caroline K.
Sharma, Animesh https://orcid.org/0000-0002-8791-4635
Bruheim, Per https://orcid.org/0000-0002-7851-8083
Otterlei, Marit https://orcid.org/0000-0002-5232-1186
- License Information
-
More Information
Article History
Received: 29 April 2022
Revised: 8 December 2022
Accepted: 13 December 2022
First Online: 23 December 2022
Competing interests
: APIM Therapeutics is a spin-off company of the Norwegian University of Science and Technology, NTNU, developing APIM-peptides for use in cancer therapy. The lead APIM-peptide ATX-101 is currently in Phase II. Professor Marit Otterlei is founder, minority shareholder and part time CSO of this company. The authors have no additional competing financial interests.
